An interventional study of Implantable cardioverter defibrillator in Coronary Artery Disease, Acute Myocardial Infarction and Ventricular Fibrillation, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark — 5 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Rigshospitalet, Denmark.
Among the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 14 with no phase, and was the 14th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark are open now, in 3 countries. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Belgium, Denmark, Netherlands
Ages 18–80
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 331 across the 15 interventional studies, 105 across the 2 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
Device: Implantable cardioverter defibrillator
Guideline directed medical therapy
Implantation of an ICD for secondary prevention
Also known as: ICD
All-cause mortality
The clinical event committee will aim to attribute the cause of death to the underlying disease process rather than the immediate mechanism. Mortality will be classified as cardiovascular and non-cardiovascular.
Time frame: 5 years
All cause mortality
Time frame: 1 year
Sudden cardiovascular death
Cardiovascular death fulfilling the following criteria: * In witnessed cases a change in cardiovascular status with time until death being \<1 hour. * In unwitnessed cases \<24 hours since last seen alive and functioning normal.
Time frame: 1 year
Cardiovascular death
Mortality is considered as cardiovascular unless it is clearly attributable to another cause and thus includes: * Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure). * Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease. * All procedure-related deaths, including those related to a complication of the ICD-procedure or treatment for a complication of the procedure. * All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events. * Death of unknown or cardiac cause.
Time frame: 1 year
Device revision or replacement due to infection or malfunction
Explorative outcome
Time frame: 1 year
Appropriate shock from an ICD (successfully treated VT/VF)
Explorative outcome
Time frame: 1 year
Inappropriate shock from an ICD (shock on non-VT/VF)
Explorative outcome
Time frame: 1 year
Register-based all cause mortality
Time frame: 10 years
Register-based sudden cardiovascular death
Time frame: 5 years
Register-based sudden cardiovascular death
Time frame: 10 years
Register-based cardiovascular death
Time frame: 5 years
Register-based cardiovascular death
Time frame: 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Oct 2032, 144 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 144 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.